{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-25-000115","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.067957+00:00","generated_at":"2026-05-17T19:53:44.708246+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GoodRx Q2 revenue $203.1M, Adj. EBITDA $69.4M; pharma segment up 32% YoY","bullets":["Revenue $203.1M, net income $12.8M (6.3% margin); adjusted net income $33.9M (16.7% margin).","Adjusted EBITDA $69.4M (34.2% margin); operating cash flow $49.6M.","Pharma Manufacturer Solutions revenue +32% YoY; new pharmacy counter deals and ED subscription launched.","Results in line with prior guidance; no explicit revision to outlook provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-25-000115","json":"https://secwatch.observer/filing/0001809519-25-000115.json","markdown":"https://secwatch.observer/filing/0001809519-25-000115.md","text":"https://secwatch.observer/filing/0001809519-25-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000115/0001809519-25-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000115/gdrx-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:53:44.708246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}